Investment in Unconsolidated Entities (Tables)

12 Months Ended

Dec. 31, 2018

Neuro Partners LLC and CGK [Member]

Schedule of Equity Method Investments [Line Items]

Equity Method Investment Summarized Financial Information

The following tables present the aggregation of summarized financial information of NeuroPartners LLC and CGK:

Neuro Partners LLC and CGK Combined Condensed Income Statement Information
	Year Ended December 31,
	2018		2017
Patient revenue	$	1,141,000	$	1,063,000
Net income	$	590,000	$	506,000
USNC’s equity in income of Neuro Partners LLC and CGK	$	181,000	$	151,000

Neuro Partners LLC and CGK Combined Condensed Balance Sheet Information
	December 31,
		2018		2017
Current assets	$	304,000	$	165,000
Noncurrent assets		1,064,000		745,000
Total assets	$	1,368,000	$	910,000
Current liabilities	$	399,000	$	641,000
Noncurrent liabilities		924,000		464,000
Equity (deficit)		45,000		(195,000	)
Total liabilities and equity (deficit)	$	1,368,000	$	910,000

FOP [Member]

Schedule of Equity Method Investments [Line Items]

Equity Method Investment Summarized Financial Information

The following tables present the summarized financial information of FOP:

FOP Condensed Income Statement Information
	Year Ended December 31,
	2018			2017
Patient revenue	$	2,953,000		$	678,000
Rental Income	$	1,252,000		$	2,517,000
Net (loss) income	$	(1,918,000	)	$	525,000
USNC’s equity in (loss) income of FOP	$	(465,000	)	$	132,000

FOP Condensed Balance Sheet Information
	December 31,
		2018			2017
Current assets	$	401,000		$	664,000
Noncurrent assets		16,570,000			18,961,000
Total assets	$	16,971,000		$	19,625,000
Current liabilities	$	3,974,000		$	3,228,000
Noncurrent liabilities		15,360,000			16,842,000
Equity		(2,363,000	)		(445,000	)
Total liabilities and equity	$	16,971,000		$	19,625,000

Boca Oncology Partners RE, LLC ("BOPRE") [Member]

Schedule of Equity Method Investments [Line Items]

Equity Method Investment Summarized Financial Information

The following tables present the summarized financial information of BOPRE:

BOPRE Condensed Income Statement Information
	Years Ended December 31,
	2018			2017
Rental Income	$	-		$	-
Net loss	$	(4,000	)	$	(7,000	)
USNC’s equity in loss in BOPRE	$	(1,000	)	$	(1,000	)

BOPRE Condensed Balance Sheet Information
	December 31,
		2018		2017
Current assets	$	18,000	$	17,000
Noncurrent assets		935,000		920,000
Total assets	$	953,000	$	937,000
Current liabilities	$	-	$	-
Noncurrent liabilities		-		-
Equity		953,000		937,000
Total liabilities and equity	$	953,000	$	937,000

Medical Oncology Partners LLC [Member]

Schedule of Equity Method Investments [Line Items]

Equity Method Investment Summarized Financial Information

The following table presents the summarized financial information of MOP:

MOP Condensed Consolidated Income Statement Information
	Years Ended December 31,
	2018			2017
Patient revenue	$	2,257,000		$	1,298,000
Net loss	$	(282,000	)	$	(272,000	)
USNC’s equity in loss in MOP	$	(101,000	)	$	(97,000	)

MOP Condensed Consolidated Balance Sheet Information
	December 31,
		2018			2017
Current assets	$	41,000		$	41,000
Noncurrent assets		159,000			108,000
Total assets	$	200,000		$	149,000
Current liabilities	$	1,002,000		$	693,000
Noncurrent liabilities		33,000			-
Deficit		(835,000	)		(544,000	)
Total liabilities and deficit	$	200,000		$	149,000

CB Oncology Partners LLC Member [Member]

Schedule of Equity Method Investments [Line Items]

Equity Method Investment Summarized Financial Information

The following table presents the summarized financial information of CBOP:

CBOP Condensed Income Statement Information
	Years Ended December 31,
	2018			2017
Patient revenue	$	956,000		$	-
Net loss	$	(1,230,000	)	$	(248,000	)
USNC’s equity in loss of CBOP	$	(298,000	)	$	(60,000	)

CBOP Condensed Balance Sheet Information
	December 31,
		2018			2017
Current assets	$	140,000		$	-
Noncurrent assets		-			-
Total assets	$	140,000		$	-
Current liabilities	$	1,618,000		$	248,000
Noncurrent liabilities		-			-
Deficit		(1,478,000	)		(248,000	)
Total liabilities and deficit	$	140,000		$	-